부산대학교 도서관

Background: The outcome of patients (pts) with neuroendocrine carcinoma (NEC) of different primary sites is generally poor. Although the initial response to chemotherapy is usually good, most pts experience a relapse. We treated 4 pts with NEC of different primary sites with high dose chemotherapy (HD Cht) and autologous peripheral stem cell transplantation (ASTx) as consolidation therapy. Methods: Pt 1 had large cell NEC of the lung. Pt 2 suffered from NEC of the pancreas. Pt 3 presented with metastatic NEC of unknown origin with multiple liver metastases and a large tumour on the upper pole of the left kidney. Pt 4 had metastatic NEC of the prostate. After 4-6 Cycles of induction chemotherapy pts received one cycle of HD Cht consisting of ifosfamide, etoposide and carboplatin, followed by unpurged ASTx. Results: Pt 1 and 2 achieved CR and died of relapse 10 and 16 month (mo) after ASTx and 16 and 22 mo after diagnosis/dg), respectively. Pt 4 obtained PR and died of tumour progression 5 mo after ASTx and 9 mo after dg. Pt 3 is still in CR with a survival of 37+ mo after ASTx and 44+ mo after dg, Conclusions: Pts with poorly differented NEC might be suitable candidates for HD Cht and ASTx. Further clinical studies are warranted to define the role of supralethal conditioning in this rare tumour entity. [ABSTRACT FROM AUTHOR]